NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court; further details about the cases can be found at the links provided.

Ormat Technologies, Inc. (NYSE:ORA) Class Period: August 8, 2017 - May 15, 2018Lead Plaintiff Deadline: August 8, 2018

During the class period, PG&E allegedly made materially false and/or misleading statements and/or failed to disclose that: PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; consequently, PG&E was in violation of state law regulation; PG&E’s electricity networks would cause numerous wildfires in California; and as a result of the foregoing, Defendants’ statements about the Company’s business and operations were materially false and misleading at all relevant times.

To learn more go to: http://www.zlk.com/pslra-d/ormat-technologies-inc?wire=3.

Newell Brands Inc. (NYSE:NWL)Class Period: February 6, 2017 - January 24, 2018Lead Plaintiff Deadline: August 20, 2018

According to the complaint, the Company’s retail channel was loaded with extremely high levels of unsold Newell product; contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance.

To learn more go to: http://www.zlk.com/pslra-d/newell-brands-inc?wire=3.

Flex Pharma, Inc. (NASDAQ:FLKS) Class Period: November 6, 2017 - June 12, 2018Lead Plaintiff Deadline: August 20, 2018

During the class period, Flex Pharma overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and as a result, Flex Pharma's public statements were materially false and misleading at all relevant times. On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.

To learn more go to: http://www.zlk.com/pslra-d/flex-pharma-inc?wire=3.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com